Deucravacitinib, a tyrosine kinase 2 inhibitor, significantly improves quality of life in patients with scalp psoriasis compared to placebo. Patients on deucravacitinib showed greater improvements ...

ORLANDO -- The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, ...

The FDA has kicked off its review of Bristol-Myers Squibb's psoriasis therapy deucravacitinib, setting an action date of 1 September next year, as the EU and Japanese regulators also start their ...

BMS isn't letting the setback dampen its enthusiasm for deucravacitinib, saying that it remains committed to developing it for IBD, and stands by its peak sales forecast for the drug of $4 billion ...

Additionally, topline results from the icotrokinra versus deucravacitinib Phase 3 ICONIC-ADVANCE 1&2d studies are summarized below: The study met its co-primary endpoints of IGA 0/1 and PASI 90 ...

standard therapy alone, according to data. ORLANDO — Twice-daily deucravacitinib 3 mg and 6 mg significantly improved cutaneous lupus erythematosus activity by week 16, according to a presenter ...

Topline results from Phase 3 ICONIC-ADVANCE 1&2�studies show icotrokinra achieved co-primary endpoints and showed superiority to deucravacitinib in moderate-to-severe plaque PsO ...

Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window ORLANDO -- The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis ...